Inventiva S.A. (0RNK.L) LSE

4.97

-0.1375(-2.69%)

Updated at September 26 04:25PM

Currency In EUR

Inventiva S.A.

Address

50 rue de Dijon

Daix, 21121

France

Phone

33 3 80 44 75 00

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

114

First IPO Date

March 30, 2017

Key Executives

NameTitlePayYear Born
Dr. Pierre Broqua Ph.D.Co-Founder, Chief Scientific Officer & Deputy Chief Executive Officer368,7261962
Mr. Frederic CrenCo-Founder, Chief Executive Officer & Director496,3681966
Mr. Jean VolatierDeputy GM & Chief Financial Officer01965
Dr. Michael Cooreman M.D., Ph.D.Chief Medical Officer01958
Mr. Eric Duranson L.L.M.General Counsel01974
Dr. Kristina Meyer Ph.D.Executive Vice President and Business Development & Alliance Management01969
Ms. Nathalie HarroyHead of Human Resources01967
Ms. Alice Roudot-Ketelers Pharm.D.Chief Operating Officer01971
Ms. Pascaline Clerc Ph.D.Executive Vice President of Strategy & Corporate Affairs01980

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.